Schonfeld Strategic Advisors LLC Buys 58,911 Shares of LivaNova PLC (NASDAQ:LIVN)

Schonfeld Strategic Advisors LLC grew its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 147.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,940 shares of the company's stock after purchasing an additional 58,911 shares during the quarter. Schonfeld Strategic Advisors LLC owned about 0.18% of LivaNova worth $4,582,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Central Pacific Bank Trust Division grew its position in LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock worth $191,000 after acquiring an additional 720 shares during the last quarter. Nordea Investment Management AB raised its position in LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock worth $3,188,000 after purchasing an additional 12,470 shares during the last quarter. Diversified Trust Co lifted its holdings in LivaNova by 9.5% during the 4th quarter. Diversified Trust Co now owns 16,432 shares of the company's stock worth $761,000 after buying an additional 1,425 shares during the period. Harbor Capital Advisors Inc. bought a new stake in shares of LivaNova in the 4th quarter valued at about $1,954,000. Finally, KBC Group NV increased its stake in shares of LivaNova by 130.5% in the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after buying an additional 56,580 shares during the period. 97.64% of the stock is owned by institutional investors.

LivaNova Stock Up 1.4 %

Shares of LIVN stock traded up $0.63 during mid-day trading on Thursday, reaching $44.13. 451,139 shares of the company's stock traded hands, compared to its average volume of 629,941. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $63.57. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company's 50-day moving average price is $37.79 and its 200-day moving average price is $45.33. The company has a market cap of $2.41 billion, a P/E ratio of 104.87 and a beta of 0.84.

Analyst Ratings Changes

Several research firms recently commented on LIVN. Wolfe Research cut LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Stifel Nicolaus cut their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. The Goldman Sachs Group lowered their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Robert W. Baird raised their price target on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday. Finally, Mizuho decreased their price objective on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $59.33.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.